| page | |
| EDITORIALS |
| 479 | Recommendations from the Medical Education Editor
|
| 482 | Development of the healthy airway smooth muscle bundles: The basis to understand airway wall remodelling
|
| 484 | Ubi pus, ibi evacua: Optimizing intrapleural fibrinolytic therapy in pleural infections
Lutz Beckert FRACP, MD, Johanna Margaretha de Koning Gans MD, Michael J Maze MB ChB, DCH, DTM&H, PhD, FRACP
10.1111/resp.14293
See related article |
| 486 | The hidden costs of living with systemic sclerosis-associated interstitial lung disease
|
| COMMENTARIES |
| 488 | Bronchiectasis enters the inflammation era
|
| 490 | Nurturing respiratory clinician-scientists—An important priority in the Asia-Pacific and for the Asia-Pacific Society of Respirology (APSR)
|
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 493 | Growth of the airway smooth muscle layer from late gestation to childhood is mediated initially by hypertrophy and subsequently hyperplasia
Kimberley C W Wang, Graham M Donovan, Sejal Saglani, Thais Mauad, Alan L James, John G Elliot, Peter B Noble
10.1111/resp.14240
A period of rapid hypertrophic airway smooth muscle growth occurs in the first year of life, representing a critical window for disruption by disease processes and/or opportunity for clinical intervention.
See related Editorial |
| Interstitial Lung Disease |
| 501 |
Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The HOMECOMIN' study
Gizal Nakshbandi, Catharina C Moor, Esther J Nossent, J J Miranda Geelhoed, Sara J Baart, Bart G Boerrigter, Joachim G J V Aerts, Suzan F M Nijman, Helger Y Santema, Merel E Hellemons, Marlies S Wijsenbeek
10.1111/resp.14262
We aimed to gain insights in the long-term recovery after coronavirus disease 2019 (COVID-19) infection using an online home monitoring programme including home spirometry. Six months after hospital admission, quality of life and lung function were still improving; however, fatigue persisted. Home monitoring enables detailed follow-up at low burden for patients and hospital systems. |
| Pleural Disease |
| 510 | Alteplase Dose Assessment for Pleural infection Therapy (ADAPT) Study-2: Use of 2.5 mg alteplase as a starting intrapleural dose
Natalia Popowicz, Hugh Ip, Estee P M Lau, Francesco Piccolo, Kirstie Dootson, Cindy Yeoh, Wint Ywe Phu, Rebecca Brown, Alex West, Liju Ahmed, Y C Gary Lee
10.1111/resp.14261
This dose de-escalation study series aims to establish the lowest effective dosing regimen of tissue plasminogen activator/deoxyribonuclease (tPA/DNase) therapy for pleural infection. We found that a starting dose of 2.5 mg tPA (with 5 mg DNase), with dose escalation if clinically needed, successfully treated 88% of patients without needing surgery.
See related Editorial |
| Pulmonary Vascular Disease |
| 517 | Characteristics, goal-oriented treatments and survival of pulmonary arterial hypertension in China: Insights from a national multicentre prospective registry
Ruilin Quan, Gangcheng Zhang, Zaixin Yu, Caojin Zhang, Zhenwen Yang, Hongyan Tian, Yuanhua Yang, Weifeng Wu, Yucheng Chen, Yuhao Liu, Xianyang Zhu, Shengqing Li, Jieyan Shen, Zeqi Zheng, Xiulong Zhu, Guangyi Wang, Qian Wang, Daxin Zhou, Yingqun Ji, Tao Yang, Wen Li, Xiaoxi Chen, Yuling Qian, Yangyi Lin, Qing Gu, Changming Xiong, Guangliang Shan, Jianguo He
10.1111/resp.14247
This Chinese registry study revealed that Chinese patients with pulmonary arterial hypertension showed both similar and distinct features compared to other countries. Many patients did not achieve low-risk profiles at follow-up, indicating more aggressive treatment should be implemented to optimize goal-oriented therapy for these patients. |
| 529 | Periostin-related progression of different types of experimental pulmonary hypertension: A role for M2 macrophage and FGF-2 signalling
Takashi Yoshida, Tetsutaro Nagaoka, Yuichi Nagata, Yoshifumi Suzuki, Takeo Tsutsumi, Sachiko Kuriyama, Junko Watanabe, Shinsaku Togo, Fumiyuki Takahashi, Masakazu Matsushita, Yusuke Joki, Hakuoh Konishi, Satoshi Nunomura, Kenji Izuhara, Simon J Conway, Kazuhisa Takahashi
10.1111/resp.14249
We demonstrated that periostin was involved in the development of different types of experimental pulmonary hypertension (PH). M2 macrophage and fibroblast growth factor-2 signalling appeared to contribute to the periostin-related progression of PH. In addition, the levels of serum periostin were significantly higher in patients with PH. |
| CONTEMPORARY CONCISE REVIEW |
| 539 | Contemporary Concise Review 2021: Interstitial lung disease
|
| LETTERS FROM ASIA-PACIFIC AND BEYOND |
| 549 |
Women in respiratory medicine: Perspectives from China Mainland and Hong Kong
Mary S M Ip MD, Huaping Dai MD
Special Series: Leading Women in Respiratory Medicine
Series Editors: Natasha Smallwood and Fanny Wai San Ko
10.1111/resp.14252
See related Editorial |
| 553 | Letter from Korea
|
| FORUM AND DEBATE |
| Correspondences |
| 555 | The ongoing impact of COVID-19 pandemic restrictions on the cardio-respiratory health of New Zealanders
|
| 558 | Increasing diagnostic yield at medical thoracoscopy
|
| 559 | Reply
|
| CORRIGENDA |
| 560 | Corrigendum
10.1111/resp.14258
This article corrects the following:
10.1111/resp.14226 |
| 561 | Corrigendum
10.1111/resp.14304
This article corrects the following:
10.1111/resp.14183 |
